SALT LAKE CITY--(BUSINESS WIRE)--Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, announced today that it will present two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans, Louisiana, April 16 through 20, 2016. The presentations include nonclinical results that further support the development of Tolero’s clinical and preclinical pipeline agents, including the CDK9 inhibitor (alvocidib) and the AXL kinase inhibitor (TP-0903).
